07:00 , Sep 14, 2015 |  BioCentury  |  Strategy

Mind melding

Novartis AG's third neuroscience deal of the summer checks two boxes for the pharma by sharing the risk for a BACE inhibitor program and adding another late-stage program in neurology, all without increasing the pharma's...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Company News

Novartis, Amgen deal

Amgen and Novartis will co-develop and co-commercialize candidates in Alzheimer’s disease and migraine. The companies said they will combine beta-site APP-cleaving enzyme (BACE) inhibitor programs to treat AD. Novartis’ BACE inhibitor CNP520 , which is...
01:38 , Sep 2, 2015 |  BC Extra  |  Company News

Amgen, Novartis enter risk-sharing CNS deal

Amgen Inc. (NASDAQ:AMGN) and Novartis AG (NYSE:NVS; SIX:NOVN) will collaborate to co-develop and co-commercialize candidates in Alzheimer's disease and migraine. The companies said they will combine beta-site APP-cleaving enzyme (BACE) inhibitor programs to treat AD....